Physician profile
Randall O Provost
NPI 1003873456
$2,910.25
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,841 · 2020: $270 · 2021: $778 · 2022: $20.73.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $359.48 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $332.56 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.50 | 2019-2021 | |
| Novo Nordisk INC | $239.90 | 2019-2021 | |
| Glaxosmithkline, LLC. | $216.82 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $211.63 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $185.43 | 2019-2021 | |
| Pfizer INC. | $180.55 | 2019-2021 | |
| Lilly USA, LLC | $124.11 | 2019 | |
| Abbvie INC. | $113.44 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $111.62 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $97.72 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $87.44 | 2019-2021 | |
| Amarin Pharma, INC. | $78.77 | 2019-2020 | |
| Medtronic, INC. | $76.10 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $51.00 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $45.42 | 2019-2021 | |
| Abbott Laboratories | $38.03 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $29.81 | 2019-2021 | |
| Medtronic Minimed, INC. | $23.30 | 2019 | |
| Dexcom, INC. | $18.91 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.33 | 2021 | |
| Xeris Pharmaceuticals, INC. | $14.77 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $13.61 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Provost listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.